Spruce Biosciences Newsroom

Congenital Adrenal Hyperplasia Landscape Research 2024: Comprehensive Insights About 8+ Pipeline Drugs Featuring Neurocrine Biosciences, Spruce Biosciences, Lundbeck, and HBM Alpha Therapeutics

Yahoo FinanceNov 21 17:06

Spruce Biosciences Faces Nasdaq Delisting Threat: Can a Reverse Stock Split Save Its Market Presence?

TipRanksNov 13 14:01

Spruce Biosciences | 10-Q: Q3 2024 Earnings Report

SECNov 13 00:47 · Announcements

Spruce Biosciences | 8-K: Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

SECNov 12 22:24

RBC Capital Maintains Spruce Biosciences(SPRB.US) With Hold Rating, Maintains Target Price $2

Futu NewsNov 12 20:36 · Ratings

RBC Capital Sticks to Their Hold Rating for Spruce Biosciences (SPRB)

TipRanksNov 12 19:38 · Ratings

Spruce Biosciences GAAP EPS of -$0.21 Beats by $0.04

Seeking AlphaNov 12 01:47

Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates

Zacks Nov 11 21:20

Express News | Spruce Biosciences: Cash, Cash Equivalents Expected to Allow Co to Fund Operating Plan Through 2025 End

BreakingsNov 11 21:02

Express News | Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

BreakingsNov 11 21:00

Press Release: Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Dow JonesNov 11 21:00

Spruce Biosciences 3Q Loss/Shr 21c >SPRB

Dow JonesNov 11 21:00

Spruce Biosciences 3Q Loss $8.67M >SPRB

Dow JonesNov 11 21:00

JMP Securities Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $3

JMP Securities analyst Jonathan Wolleben maintains $Spruce Biosciences(SPRB.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 4

Futu NewsSep 11 09:32 · Ratings

Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Yahoo FinanceSep 4 04:01

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)

TipRanksAug 20 15:02 · Ratings

HC Wainwright & Co. Reiterates Neutral on Spruce Biosciences

Analyst UpgradesAug 19 20:30

H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Hold Rating

H.C. Wainwright analyst Ram Selvaraju maintains $Spruce Biosciences(SPRB.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 42.2% and a total average return of 1.6%

Futu NewsAug 19 18:31 · Ratings

Analysts' Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and ScPharmaceuticals (SCPH)

TipRanksAug 19 18:30 · Ratings

RBC Capital Reiterates Sector Perform on Spruce Biosciences, Maintains $2 Price Target

BenzingaAug 14 00:29 · Ratings